 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...147148149150151152153154155156157...235236» |
- | leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Journal: Leucovorin ameliorated methotrexate induced intestinal toxicity via modulation of the gut microbiota. (Pubmed Central) - Aug 18, 2020
In conclusion, our results suggest that the balance and the composition of gut microbiota have an important role in the LV-mediated protection against MTX-induced intestinal toxicity. This work provides foundation of data in support of a new potential mechanism for the prevention of MTX-induced intestinal toxicity.
- || leucovorin calcium / Generic mfg.
Clinical, Journal: Caesarean scar pregnancy: descriptive paper of three different types of management on a series of clinical cases. (Pubmed Central) - Aug 18, 2020
In our preliminary study, we highlighted how our experimental protocol gave encouraging results in the first 10 weeks of caesarean scar pregnancy. However, caution is needed in patients with advanced gestational age, a gestational sac with large diameter, higher CRL and presence of embryonic cardiac activity.
- | Trial completion date, Trial termination, Metastases: Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Aug 18, 2020
P1, N=25, Terminated, Sponsor: University of Alabama at Birmingham
However, caution is needed in patients with advanced gestational age, a gestational sac with large diameter, higher CRL and presence of embryonic cardiac activity. Trial completion date: Jul 2021 --> Jul 2020 | Recruiting --> Terminated; PI left the institution; no further accruals
- ||| leucovorin calcium / Generic mfg., methotrexate / Generic mfg., Neupogen (filgrastim) / Kyowa Hakko Kirin, Roche, Amgen
Clinical, Journal, Adverse events: Nephrotoxicity Associated with Low-dose Methotrexate and Outpatient Parenteral Microbial Therapy: A Case Report, Review of the Literature and Pathophysiologic Insights. (Pubmed Central) - Aug 18, 2020
Her renal function continued to be reduced at 5-week outpatient follow-up, far after other markers of toxicity normalized. This case demonstrates the importance of considering potential drug-drug interactions and the need for robust monitoring for OPAT in select groups.
- | Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, Metastases: GEMFOX: FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX (clinicaltrials.gov) - Aug 18, 2020
P3, N=400, Recruiting, Sponsor: Assistance Publique - H
This case demonstrates the importance of considering potential drug-drug interactions and the need for robust monitoring for OPAT in select groups. Not yet recruiting --> Recruiting | Trial completion date: Jan 2025 --> Jul 2025 | Initiation date: Jan 2020 --> Jul 2020 | Trial primary completion date: Jan 2025 --> Jul 2025
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
New P3 trial, Metastases: Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 17, 2020
P3, N=400, Recruiting, Sponsor: Fudan University
- | Enrollment closed, Enrollment change, Trial primary completion date: Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Aug 17, 2020
P2, N=24, Active, not recruiting, Sponsor: Albert Einstein College of Medicine
Not yet recruiting --> Recruiting | Trial completion date: Jan 2025 --> Jul 2025 | Initiation date: Jan 2020 --> Jul 2020 | Trial primary completion date: Jan 2025 --> Jul 2025 Recruiting --> Active, not recruiting | N=50 --> 24 | Trial primary completion date: Jan 2017 --> Jun 2022
- | Tyvyt (sintilimab) / Eli Lilly
Enrollment closed, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: TAIPD1-HCC: HAIC Combined With PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC (clinicaltrials.gov) - Aug 17, 2020
P2, N=40, Active, not recruiting, Sponsor: Sun Yat-sen University
Recruiting --> Active, not recruiting | N=50 --> 24 | Trial primary completion date: Jan 2017 --> Jun 2022 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2021 --> Jul 2020
- | leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Journal: Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma. (Pubmed Central) - Aug 15, 2020
Methotrexate (MTX) in tumor cells is polyglutamylated and strongly binds to dihydrofolate reductase (DHFR) without competitive inhibition by leucovorin...Combination treatments were created using 4 HDACIs: panobinostat, vorinostat, sodium butyrate, and valproic acid...The combination of MTX and vorinostat decreased cell viability in vitro (P < .05) and tumor volumes in a subcutaneous model (P < .0001), and prolonged survival in an intracranial model (P < .01), relative to controls. HDACIs enhanced the therapeutic effect of MTX through increased polyglutamylation of MTX and concomitant downregulation of DHFR expression.
- || Trial completion date, Trial primary completion date: OPRA: Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management (clinicaltrials.gov) - Aug 14, 2020
P2, N=325, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
HDACIs enhanced the therapeutic effect of MTX through increased polyglutamylation of MTX and concomitant downregulation of DHFR expression. Trial completion date: Nov 2020 --> Nov 2021 | Trial primary completion date: Nov 2020 --> Nov 2021
- | Bavencio (avelumab) / EMD Serono
Trial primary completion date, Combination therapy, Metastases: Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 (clinicaltrials.gov) - Aug 14, 2020
P2, N=27, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Nov 2020 --> Nov 2021 | Trial primary completion date: Nov 2020 --> Nov 2021 Trial primary completion date: Aug 2020 --> Jul 2021
- || dalutrafusp alfa (AGEN1423) / Agenus
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Aug 13, 2020
P1a/1b, N=213, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Aug 2020 --> Jul 2021 Trial completion date: Dec 2024 --> Aug 2026 | Trial primary completion date: Nov 2021 --> Aug 2025
- | Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly
New P2 trial: AVETRIC: AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Aug 13, 2020
P2, N=58, Recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
- ||| leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
NCCN guideline, Journal: NCCN Guidelines Updates: Pancreatic Cancer. (Pubmed Central) - Aug 13, 2020
The NCCN Guidelines for Pancreatic Adenocarcinoma reflect these advances, and recommend that clinicians consider germline testing for all patients with pancreatic cancer and consider a molecular analysis for those with metastatic disease. The guidelines further recommend that clinicians consider adjuvant therapy with modified FOLFIRINOX (leucovorin/5-FU/irinotecan/oxaliplatin) for patients who are able to tolerate it.
- | GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis
Trial completion date, Trial primary completion date, Tumor cell: Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Aug 13, 2020
P=N/A, N=19, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The guidelines further recommend that clinicians consider adjuvant therapy with modified FOLFIRINOX (leucovorin/5-FU/irinotecan/oxaliplatin) for patients who are able to tolerate it. Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Aug 2021
- ||| sirexatamab (DKN-01) / Leap Therap
Enrollment open, Combination therapy, Metastases: DisTinGuish: A Study of DKN-01 in Combination With Tislelizumab (clinicaltrials.gov) - Aug 12, 2020
P2a, N=72, Recruiting, Sponsor: Leap Therapeutics, Inc.
Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Aug 2021 Not yet recruiting --> Recruiting
- Trial completion date, Trial primary completion date: QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - Aug 12, 2020
P1/2, N=3, Active, not recruiting, Sponsor: NantKwest, Inc.
Not yet recruiting --> Recruiting Trial completion date: Dec 2018 --> Apr 2021 | Trial primary completion date: Oct 2018 --> Dec 2020
- || Tukysa (tucatinib) / Pfizer
Enrollment open: SGNTUC 024: Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers (clinicaltrials.gov) - Aug 11, 2020
P1b, N=30, Recruiting, Sponsor: Seattle Genetics, Inc.
Trial completion date: Dec 2018 --> Apr 2021 | Trial primary completion date: Oct 2018 --> Dec 2020 Not yet recruiting --> Recruiting
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Avastin (bevacizumab) / Roche
Enrollment open, Metastases: HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC (clinicaltrials.gov) - Aug 11, 2020
P2, N=32, Recruiting, Sponsor: Peking University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, PharmaEngine
Clinical, Journal, Combination therapy: Nanoliposomal Irinotecan in Combination with Fluorouracil and Folinic Acid, As a New Option for Second-Line Treatment in Metastatic Pancreatic Cancer (Pubmed Central) - Aug 11, 2020
This paper provides an overview of development of this new nal-IRI plus FF therapy and relevant information. Drug therapies for pancreatic cancer currently being developed in Japan, as well as the position of this therapy in pancreatic cancer therapy in Japan and what the expectations are in the clinical setting, are also discussed.
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
Review, Journal, BRCA Biomarker, PARP Biomarker, IO Biomarker: Pancreatic cancer. (Pubmed Central) - Aug 11, 2020
Data on the benefit of PARP inhibition as maintenance therapy in patients with germline BRCA1 or BRACA2 mutations might prove to be a harbinger of advancement in targeted therapy. Additional research efforts are focusing on modulating the pancreatic tumour microenvironment to enhance the efficacy of the immunotherapeutic strategies.
- | vancomycin / Generic mfg., leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Journal: Low-dose Methotrexate Toxicity in the Setting of Vancomycin-induced Acute Kidney Injury. (Pubmed Central) - Aug 11, 2020
The condition was managed with leucovorin rescue therapy and sodium bicarbonate to enhance methotrexate excretion. Renally dosing methotrexate in patients on other nephrotoxic drugs, and monitoring creatinine clearance are methods for preventing such a toxicity.
- || Trial completion date, Trial primary completion date: QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed (clinicaltrials.gov) - Aug 11, 2020
P1/2, N=65, Active, not recruiting, Sponsor: NantKwest, Inc.
Renally dosing methotrexate in patients on other nephrotoxic drugs, and monitoring creatinine clearance are methods for preventing such a toxicity. Trial completion date: Dec 2019 --> Apr 2021 | Trial primary completion date: Dec 2019 --> Jan 2021
- || Trial completion date, Trial primary completion date: QUILT-3.060t: QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - Aug 11, 2020
P1/2, N=80, Active, not recruiting, Sponsor: NantKwest, Inc.
Trial completion date: Dec 2019 --> Apr 2021 | Trial primary completion date: Dec 2019 --> Jan 2021 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Nov 2018 --> Dec 2020
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, Mismatch repair: CheckMate 8HW: A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Aug 10, 2020
P3b, N=494, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Nov 2018 --> Dec 2020 Trial primary completion date: Oct 2024 --> Aug 2025
- | Biomarker, Trial initiation date: Neoadjuvant Therapy for Localized Rectal Adenocarcinoma (clinicaltrials.gov) - Aug 10, 2020
P2, N=45, Not yet recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Oct 2024 --> Aug 2025 Initiation date: Jun 2020 --> Sep 2020
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Trial completion date, Trial primary completion date, Metastases: NCI-2018-02122: Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin (clinicaltrials.gov) - Aug 10, 2020
P2, N=37, Recruiting, Sponsor: Roswell Park Cancer Institute
Initiation date: Jun 2020 --> Sep 2020 Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Sep 2021 --> Sep 2022
- | Odomzo (sonidegib) / Sun Pharma
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer (clinicaltrials.gov) - Aug 9, 2020
P1b, N=39, Completed, Sponsor: Massachusetts General Hospital
Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Sep 2021 --> Sep 2022 Active, not recruiting --> Completed | Trial completion date: Mar 2019 --> Nov 2019 | Trial primary completion date: Mar 2019 --> Nov 2019
- | Trial completion, Metastases: LAPC-1: Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer. (clinicaltrials.gov) - Aug 9, 2020
P=N/A, N=53, Completed, Sponsor: Foundation for Liver Research
Active, not recruiting --> Completed | Trial completion date: Mar 2019 --> Nov 2019 | Trial primary completion date: Mar 2019 --> Nov 2019 Active, not recruiting --> Completed
- | Trial completion date, Trial primary completion date, Metastases: SEQUENCE: Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Aug 9, 2020
P1/2, N=168, Active, not recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Active, not recruiting --> Completed Trial completion date: Apr 2020 --> Sep 2020 | Trial primary completion date: Apr 2020 --> Sep 2020
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy: A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors (clinicaltrials.gov) - Aug 8, 2020
P1, N=430, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Apr 2020 --> Sep 2020 | Trial primary completion date: Apr 2020 --> Sep 2020 Trial completion date: Jan 2021 --> Sep 2021 | Trial primary completion date: Jan 2021 --> Sep 2021
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment closed: AALL1621: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 8, 2020
P2, N=53, Active, not recruiting, Sponsor: Children's Oncology Group
Trial completion date: Jan 2021 --> Sep 2021 | Trial primary completion date: Jan 2021 --> Sep 2021 Suspended --> Active, not recruiting
- | Avastin (bevacizumab) / Roche
Enrollment open, Metastases: Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer (clinicaltrials.gov) - Aug 8, 2020
P1, N=52, Recruiting, Sponsor: M.D. Anderson Cancer Center
Suspended --> Active, not recruiting Not yet recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: BTCRC-GI15-015: FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma (clinicaltrials.gov) - Aug 8, 2020
P2, N=39, Recruiting, Sponsor: Al B. Benson, III, MD
Not yet recruiting --> Recruiting Trial completion date: Jun 2021 --> Aug 2022 | Trial primary completion date: Jun 2020 --> Aug 2021
- | Trial completion date, Trial primary completion date, Metastases: Short-course Radiotherapy (5 (clinicaltrials.gov) - Aug 8, 2020
P1, N=9, Recruiting, Sponsor: Fujian Medical University Union Hospital
Trial completion date: Jun 2021 --> Aug 2022 | Trial primary completion date: Jun 2020 --> Aug 2021 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
- | Enrollment closed, Trial completion date, Trial primary completion date: PENCOLA: Peripheral Neuropathy in Colorectal Cancer Patients Under Adjuvant Chemotherapy With FOLFOX, FLOX or XELOX Regime (clinicaltrials.gov) - Aug 8, 2020
P=N/A, N=30, Active, not recruiting, Sponsor: Lund University Hospital
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Jun 2020 --> Jun 2021 Recruiting --> Active, not recruiting | Trial completion date: Mar 2020 --> Sep 2020 | Trial primary completion date: Mar 2020 --> Sep 2020
- ||| bemarituzumab (AMG 552) / Amgen
Phase classification, Enrollment change, Metastases: FIGHT: A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (clinicaltrials.gov) - Aug 8, 2020
P2, N=155, Active, not recruiting, Sponsor: Five Prime Therapeutics, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Mar 2020 --> Sep 2020 | Trial primary completion date: Mar 2020 --> Sep 2020 Phase classification: P3 --> P2 | N=548 --> 155
- || Opdivo (nivolumab) / BMS
Trial primary completion date: CA209-8TT: Pan Tumor Rollover Study (clinicaltrials.gov) - Aug 7, 2020
P2, N=1200, Recruiting, Sponsor: Bristol-Myers Squibb
Phase classification: P3 --> P2 | N=548 --> 155 Trial primary completion date: Dec 2022 --> Aug 2025
- | Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / BMS
Enrollment open, Tumor mutational burden: NIVACOR: Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients (clinicaltrials.gov) - Aug 7, 2020
P2, N=70, Recruiting, Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica
Trial primary completion date: Dec 2022 --> Aug 2025 Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche
Enrollment open, Metastases: Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab (clinicaltrials.gov) - Aug 7, 2020
P1, N=20, Recruiting, Sponsor: Anne Noonan
Not yet recruiting --> Recruiting Suspended --> Recruiting
- | Cyramza (ramucirumab) / Eli Lilly
Enrollment open, Trial initiation date, Metastases: SWOG S1922: Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers (clinicaltrials.gov) - Aug 7, 2020
P2, N=94, Recruiting, Sponsor: Southwest Oncology Group
Suspended --> Recruiting Not yet recruiting --> Recruiting | Initiation date: May 2020 --> Dec 2019
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P3 trial, Metastases: Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Aug 6, 2020
P3, N=818, Not yet recruiting, Sponsor: Ralf Hofheinz
- || oxaliplatin / Generic mfg., fluorouracil / Generic mfg.
Clinical, P2 data, Journal, Monotherapy: Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC). (Pubmed Central) - Aug 6, 2020
P2
Results are intended for publication in peer-reviewed medical journals and for presentation to patients, healthcare professionals and other stakeholders. NCT03246321, Pre-results; ISRCTN89947480, Pre-results; NTR6603, Pre-results; EudraCT: 2017-000927-29, Pre-results.
- | leucovorin calcium / Generic mfg.
Journal: Characteristics of emergency department presentations requiring consultation of the national Poisons Information Centre. (Pubmed Central) - Aug 4, 2020
For patients presenting at the emergency department with severe poisoning, contact with the poison information centre can help to implement specific treatment and avoid fatalities. In less severe cases involving more common agents (e.g. paracetamol, benzodiazepines), contact can help to avoid unnecessary treatment and serve as a source of information and/or confirmation.
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., Avastin (bevacizumab) / Roche
Clinical, Journal: Penile metastasis in rectal cancer with pathologic complete response after neoadjuvant chemoradiotherapy: The first case report and literature review. (Pubmed Central) - Aug 4, 2020
The patient is still alive 4 months after diagnosis with markedly decreased metastatic lesions. We propose that although penile metastasis in rectal cancer with pCR after preoperative neoadjuvant CRT is extremely rare, it might help to start early palliative chemotherapy and clinicians should be aware of this possibility.
- | leucovorin calcium / Generic mfg.
Review, Journal: Cerebral folate deficiency: Analytical tests and differential diagnosis. (Pubmed Central) - Aug 2, 2020
Other secondary causes of cerebral folate deficiency include the effects of drugs, immune response activation, toxic insults and oxidative stress. This review describes the absorption, transport and metabolism of folate within the body; analytical methods to measure folate species in blood, plasma and CSF; inherited and acquired causes of cerebral folate deficiency; and possible treatment options in those patients found to have cerebral folate deficiency.
- || Clinical, Journal, Real-World Evidence: Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis. (Pubmed Central) - Aug 2, 2020
The results suggest that the modified schedules often used in this daily clinical practice-based patient population are associated with less severe toxicity without apparent detriment to survival endpoints. It is believed that these data complement the information provided by the VELOUR trial and are relevant for the oncologist in treating colon cancer in the second-line setting.
- || Clinical, P1/2 data, Journal: A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study. (Pubmed Central) - Aug 2, 2020
P1/2, P2
Biweekly SLOG is a feasible regimen with promising activity and safety profiles. A randomised study comparing SLOG versus modified folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) in advanced PDAC is ongoing (ClinicalTrials.gov: NCT03443492).
- | Journal: Twenty-five-Year Follow-up of a Prospective Randomized Trial Comparing Preoperative Versus Postoperative FLAC/Granulocyte Colony-Stimulating Factor Chemotherapy for Stage II Breast Cancer. (Pubmed Central) - Aug 2, 2020
A randomised study comparing SLOG versus modified folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) in advanced PDAC is ongoing (ClinicalTrials.gov: NCT03443492). Twenty-five-year follow-up for this prospective randomized trial confirms the equivalency of preoperative versus postoperative chemotherapy with fluorouracil, leucovorin calcium, doxorubicin, and cyclophosphamides/granulocyte colony-stimulating factor for stage II breast cancer for both RFS and OS.
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., Avastin (bevacizumab) / Roche
Clinical, Journal: Appendiceal Goblet Cell Carcinoid Successfully Treated with Bevacizumab plus mFOLFOX6 Regimen-A Case Report (Pubmed Central) - Jul 30, 2020
Intraoperative findings included multiple disseminated nodules on the mesenterium surrounding the cecal tumor.The histopathologic diagnosis was poorly differentiated adenocarcinoma, which consisted of glandular proliferation of atypical epithelial cells and dispersed infiltration of goblet cells. Immunohistochemistry showed positively stained neuroendocrine markers, such as CD56, chromogranin, and synaptophysin.The patient was diagnosed with goblet cell carcinoid of the appendix and treated with combination chemotherapy of bevacizumab, fluorouracil, folinic acid, and oxaliplatin.He remained free from progression for over 1 and half years with this treatment.Subsequent chemotherapy was ineffective, and he passed away.There is no established chemotherapy regimen for goblet cell carcinoid, which has the aspects of both adenocarcinoma and neuroendocrine tumors.However, the present case suggested the efficacy of the mFOLFOX6 regimen in combination with bevacizumab for appendiceal goblet cell carcinoid.